Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VISINE vs PREFRIN-A
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tetrahydrozoline is a sympathomimetic amine that acts as an alpha-1 adrenergic receptor agonist, causing vasoconstriction of conjunctival blood vessels, thereby reducing redness and edema.
PREFRIN-A contains phenylephrine, an alpha-1 adrenergic receptor agonist, and acetaminophen, a centrally acting analgesic and antipyretic. Phenylephrine causes vasoconstriction in nasal mucosa, reducing congestion. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the brain, reducing prostaglandin synthesis.
Relief of ocular redness due to minor irritations,Off-label: symptomatic treatment of allergic conjunctivitis
Temporary relief of nasal congestion,Fever reduction,Mild to moderate pain relief
1-2 drops in affected eye(s) every 6-8 hours as needed, not to exceed 4 times daily.
1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily.
Approximately 1-2 hours for ocular absorption; systemic half-life not clinically relevant due to low systemic absorption
Terminal elimination half-life: 2-4 hours in adults; 6-12 hours in neonates and infants due to immature hepatic metabolism.
Not systemically absorbed; no significant metabolism occurs in the eye.
Phenylephrine undergoes extensive first-pass metabolism by monoamine oxidase (MAO) in the liver and gut; acetaminophen is primarily metabolized by glucuronidation and sulfation, with minor CYP2E1 oxidation to a hepatotoxic metabolite NAPQI.
Primarily renal as unchanged drug and metabolites; minor biliary/fecal elimination (<10%)
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30% as metabolites.
Approximately 80% bound to plasma proteins, primarily albumin
Phenylephrine: 50-60% bound to albumin and alpha-1-acid glycoprotein; Antazoline: ~20% bound to albumin.
Not clinically significant for topical ophthalmic use; systemic Vd estimated at 0.5-1 L/kg based on IV data
Phenylephrine: Vd ~0.5 L/kg (distributes primarily into extracellular fluid); Antazoline: Vd ~2 L/kg (extensive tissue distribution).
Ocular: negligible systemic bioavailability (<1% from topical dose); oral not applicable
Ocular: <1% systemic bioavailability after topical administration; intranasal: 10-20% systemic bioavailability; oral: 2-5% due to first-pass metabolism.
No dose adjustment required; systemic absorption is minimal.
No dosage adjustment required for renal impairment.
No dose adjustment required; systemic absorption is minimal.
No dosage adjustment required for hepatic impairment.
Children 6 years and older: 1 drop in affected eye(s) every 6-8 hours as needed, not to exceed 4 times daily. Safety and efficacy in children under 6 years not established.
Children ≥6 years: 1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily. Children <6 years: not recommended.
No specific dose adjustment, but use with caution due to increased risk of systemic effects (e.g., hypertension, cardiac arrhythmias) and potential for angle-closure glaucoma.
Use with caution due to increased risk of systemic absorption and adverse effects; consider lowest effective dose and frequency.
None
None.
Do not use in patients with narrow-angle glaucoma; overuse may cause rebound hyperemia; avoid in children under 6 years; discontinue if eye pain or vision changes occur.
Avoid use in patients with hypertension, hyperthyroidism, diabetes, or cardiovascular disease. Risk of hepatotoxicity with acetaminophen overdose. Do not exceed recommended dose. Avoid concurrent use with MAO inhibitors.
Hypersensitivity to tetrahydrozoline or any component; narrow-angle glaucoma; concurrent use with MAO inhibitors
Hypersensitivity to phenylephrine, acetaminophen, or any excipients. Severe hypertension or coronary artery disease. Concomitant use or within 14 days of MAO inhibitors.
No known food interactions. Avoid alcohol as it may exacerbate eye redness or irritation.
Avoid alcohol and products containing caffeine or other stimulants as they may increase the risk of cardiovascular adverse effects. No specific food restrictions beyond maintaining hydration.
No evidence of teratogenicity in animal studies. In humans, limited data; topical ocular use results in negligible systemic absorption. First trimester: theoretical risk minimal. Second and third trimesters: no specific risks identified. However, avoid prolonged use due to potential vasoconstrictive effects.
Phenylephrine (sympathomimetic) and pyrilamine (antihistamine) combination. No adequate well-controlled studies in pregnant women. Phenylephrine may cause uterine vasoconstriction and reduced placental perfusion; risk of fetal hypoxia in third trimester. Pyrilamine: Class B in pregnancy; animal studies show no fetal harm. Avoid in first trimester due to theoretical risk of vasoconstriction. Use only if benefit outweighs risk.
Negligible systemic absorption with topical ocular use; M/P ratio not determined. Excretion into breast milk unlikely. Considered compatible with breastfeeding; use caution with excessive or prolonged use.
Phenylephrine: minimal excretion in breast milk; M/P ratio unknown. Pyrilamine: not known if excreted. Antihistamines may cause drowsiness or irritability in infant. Avoid if possible due to lack of safety data. Consider alternative with more data.
No dose adjustments necessary for pregnancy as systemic absorption is negligible. Standard dosing (1-2 drops every 8-12 hours) applies. Avoid overuse due to potential for rebound congestion or systemic effects.
No specific dose adjustment recommendations due to lack of pharmacokinetic studies in pregnancy. Use lowest effective dose for shortest duration. Consider alternative agents if possible.
Visine (tetrahydrozoline) is a topical ocular decongestant; prolonged use (>72 hours) can cause rebound hyperemia and conjunctivitis medicamentosa. Avoid in patients with narrow-angle glaucoma, cardiovascular disease, or hypertension. Do not use in children under 2 years without medical advice.
Prefrin-A combines phenylephrine (alpha-1 agonist vasoconstrictor) with pyrilamine (first-generation antihistamine). Use with caution in patients with hypertension, cardiovascular disease, hyperthyroidism, diabetes, or narrow-angle glaucoma. Avoid in patients taking MAO inhibitors or within 14 days of discontinuation. Rebound congestion can occur with prolonged use (>3 days). Monitor for CNS depression or paradoxical excitation in children.
Do not use Visine for more than 3 days to avoid rebound redness.,Remove contact lenses before instilling drops and wait at least 15 minutes before reinserting.,Do not share the bottle to prevent infection.,Avoid touching the dropper tip to any surface or the eye.,If eye pain, vision changes, or persistent redness occur, discontinue use and consult a doctor.
Use exactly as directed; do not use for more than 3 days to avoid rebound congestion.,Avoid driving or operating machinery if drowsiness occurs, especially when combined with alcohol or other CNS depressants.,Do not use if you have high blood pressure, heart disease, thyroid problems, diabetes, or glaucoma unless directed by a doctor.,Discontinue use and consult a doctor if symptoms persist or worsen, or if you experience severe dizziness, headache, or irregular heartbeat.,Store at room temperature away from moisture and heat. Keep out of reach of children.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VISINE vs PREFRIN-A, answered by our medical review team.
VISINE is a Ophthalmic Decongestant that works by Tetrahydrozoline is a sympathomimetic amine that acts as an alpha-1 adrenergic receptor agonist, causing vasoconstriction of conjunctival blood vessels, thereby reducing redness and edema.. PREFRIN-A is a Ophthalmic Decongestant/Antihistamine Combination that works by PREFRIN-A contains phenylephrine, an alpha-1 adrenergic receptor agonist, and acetaminophen, a centrally acting analgesic and antipyretic. Phenylephrine causes vasoconstriction in nasal mucosa, reducing congestion. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the brain, reducing prostaglandin synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VISINE and PREFRIN-A depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VISINE is: 1-2 drops in affected eye(s) every 6-8 hours as needed, not to exceed 4 times daily.. The standard adult dose of PREFRIN-A is: 1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VISINE and PREFRIN-A in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VISINE is classified as Category C. No evidence of teratogenicity in animal studies. In humans, limited data; topical ocular use results in negligible systemic absorption. First trimester: theoretical risk minimal. S. PREFRIN-A is classified as Category C. Phenylephrine (sympathomimetic) and pyrilamine (antihistamine) combination. No adequate well-controlled studies in pregnant women. Phenylephrine may cause uterine vasoconstriction . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.